Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menactra Antibody Persistence and Booster Response
NCT00700713Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of meningococcal A conjugate vaccine in meningococcal meningitis and meningococcemia (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Serum Meningococcal Serogroups A, C, Y, and W-135 Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 at Day 30. Started Jun 2008; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal meningitismeningococcemia
Beyond the preview
Go deeper on NCT00700713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00700713.